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BACKGROUND: Human papillomavirus vaccines prevent human infections or decrease incidence of cytologic/histologic abnormalities
papillomavirus infection and cervical precancers. The impact of vacci-
nating women with a current infection or after treatment for an human
papillomavirus-associated lesion is not fully understood.
OBJECTIVES: To determine whether human papillomavirus-16/18
vaccination influences the outcome of infections present at vaccination
and the rate of infection and disease after treatment of lesions.
STUDY DESIGN: We included 1711 women (1825 years) with
carcinogenic human papillomavirus infection and 311 women of similar
age who underwent treatment for cervical precancer and who participated
in a community-based trial of the AS04-adjuvanted human
papillomavirus-16/18 virus-like particle vaccine. Participants were ran-
domized (human papillomavirus or hepatitis A vaccine) and offered 3
vaccinations over 6 months. Follow-up included annual visits (more
frequently if clinically indicated), referral to colposcopy of high-grade and
persistent low-grade lesions, treatment by loop electrosurgical excisional
procedure when clinically indicated, and cytologic and virologic follow-up
after treatment. Among women with human papillomavirus infection at the
time of vaccination, we considered type-specific viral clearance, and
development of cytologic (squamous intraepithelial lesions) and histologic
(cervical intraepithelial neoplasia) lesions. Among treated women, we
considered single-time and persistent human papillomavirus infection,
squamous intraepithelial lesions, and cervical intraepithelial neoplasia 2 or
greater. Outcomes associated with infections absent before treatment also
were evaluated. Infection-level analyses were performed and vaccine
efficacy estimated.
RESULTS: Median follow-up was 56.7 months (women with human
papillomavirus infection) and 27.3 months (treated women). There was no
evidence of vaccine efficacy to increase clearance of human papillomavirusCite this article as: Hildesheim A, Gonzalez P, Kreimer
AR, et al. Impact of human papillomavirus (HPV) 16 and
18 vaccination on prevalent infections and rates of cer-
vical lesions after excisional treatment. Am J Obstet
Gynecol 2016;215:212.e1-15.
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efficacy for human papillomavirus 16/18 clearance and against human
papillomavirus 16/18 progression from infection to cervical intraepithelial
neoplasia 2 or greater were5.4% (95% confidence interval19,10) and
0.3% (95% confidence interval 69,41), respectively. Among treated
women, 34.1% had oncogenic infection and 1.6% had cervical intra-
epithelial neoplasia 2 or greater detected after treatment, respectively, and
of these 69.8% and 20.0% were the result of new infections. We observed
no significant effect of vaccination on rates of infection/lesions after
treatment. Vaccine efficacy estimates for human papillomavirus 16/18
associated persistent infection and cervical intraepithelial neoplasia 2 or
greater after treatment were 34.7% (95% confidence interval 131, 82)
and 211% (95% confidence interval 2901, 68), respectively. We
observed evidence for a partial and nonsignificant protective effect of
vaccination against new infections absent before treatment. For incident
human papillomavirus 16/18, human papillomavirus 31/33/45, and
oncogenic human papillomavirus infections post-treatment, vaccine effi-
cacy estimates were 57.9% (95% confidence interval 43, 88), 72.9%
(95% confidence interval 29, 90), and 36.7% (95% confidence interval 1.5,
59), respectively.
CONCLUSION: We find no evidence for a vaccine effect on the fate of
detectable human papillomavirus infections. We show that vaccination
does not protect against infections/lesions after treatment. Evaluation of
vaccine protection against new infections after treatment and resultant
lesions warrants further consideration in future studies.
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prevention, vaccineshe human papillomavirus (HPV)T L1 virus-like particle vaccines ﬁrst
licensed in 2006 have been shown to behighly effective for prophylaxis of HPV
infection, which in turn reduces rates of
HPV-associated precancer lesions.1-3
The high efﬁcacy of these vaccines is
thought to be explained by the induction
of neutralizing antibodies that protect
against infection by binding to virions
and preventing them from infecting
human cells.4
Among HPV-infected individuals,
neutralizing antibodies induced by
vaccination could hypothetically bind
to virions produced by infected cells,
reducing spread of an existing infectionby limiting the ability of the virus
to infect new cells in the infected indi-
vidual. It is also possible that vaccine-
induced, cell-mediated immune re-
sponses to L1 promote clearance of
infected cells.5 Initial efforts to evaluate
such a “secondary” effect of the vaccine,
however, suggested that vaccination did
not lead to faster clearance or reduced
persistence of prevalent infections.6-8
More recently, ﬁndings from both
randomized and nonrandomized studies
have suggested a possible beneﬁt of
vaccination to prevent the recurrence of
ajog.org GYNECOLOGY Original Researchgenital lesions after excisional treatment
of prevalent disease, once again raising
the possibility of a beneﬁcial effect of
vaccination of individuals already infec-
ted with HPV.9-11 One study of women
treated for cervical or vaginal HPV-
associated disease observed that rates of
disease after treatment were reduced
among those whowere vaccinated before
treatment (46.2% vaccine efﬁcacy
against recurrent HPV-related disease),
an effect that was stronger for cervical
than noncervical disease.9 A similar ef-
fect was observed in a nonrandomized
study that vaccinated women after
treatment for cervical disease was
completed (65.3% reduction in the rate
of recurrent cervical intraepithelial
neoplasia type 2-3, or CIN2-3).10 A third
study of men who have sex with men
treated for high-grade anal intra-
epithelial neoplasia reported that rates of
disease after treatment also were reduced
among those whowere vaccinated before
treatment (55.7% reduction in the rate
of recurrent high-grade anal intra-
epithelial lesions).11 The later study was
not randomized, and unvaccinated men
had more time than vaccinated men
from treatment to enrollment into the
study, raising the possibility that efﬁcacy
estimates were biased in favor of the
vaccine.
Of note, none of the aforementioned
reports evaluate whether the observed
effects resulted from (1) a therapeutic
effect on residual infection directly or
through reduced ability of residual virus
to infect new cells (“secondary” effect) or
(2) beneﬁt of vaccination on de novo
primary lesions caused by a new HPV
infections after treatment (prophylactic
effect).
We previously reported on the lack of
efﬁcacy of HPV-16/18 vaccination on
clearance of infections present at vacci-
nation from a large, community-based
randomized clinical trial in rural Costa
Rica.6 Given the recent, previously
summarized data suggesting a possible
role for HPV vaccination after treatment
of cervical lesions, we report herein a re-
evaluation of data from Costa Rica by
expanding the study in 3 important
ways. First, we evaluated the effect of
vaccination on HPV clearance in a largernumber of participants followed for a
longer period of time. Second, we eval-
uated the impact of vaccination on the
rate of progression of prevalent infection
to precancer (not available in our pre-
vious report). Finally, we evaluated the
impact of vaccination on the rate of
infection and disease after excisional
treatment for cervical disease. For the
latter analysis, we further evaluated
whether lesions occur in a background
of unresolved infection and/or new in-
fections after treatment, in an attempt to
better understand the underlying
mechanism of any observed vaccine ef-
fects (ie, recurrence caused by residual
infection vs primary prevention).
Methods
Women included in the present evalua-
tion were participants in a larger
community-based randomized clinical
trial of 7466 Costa Rican women 1825
years of age at enrollment (June 2004 to
December 2005) that evaluated the efﬁ-
cacy of the HPV-16/18 viruslike par-
ticle vaccine formulated with the AS04
adjuvant system (Cervarix; GSK Bi-
ologicals, Rixensart, Belgium) against
persistent type-speciﬁc infection with
HPV and HPV-associated precancerous
lesions. The design and methods for this
trial have been described in detail pre-
viously and involved randomization,
vaccination (3 doses offered over 6
months), active annual (or more
frequently if clinically indicated) follow-
up, referral to colposcopy of high-grade
precancers and/or persistent low-grade
cervical lesions, and treatment by loop
electrosurgical excisional procedure
(LEEP) when clinically indicated.12
For the present analyses, we included
2 groups of women. The ﬁrst consisted
of participants who, at entry into the
trial, were infected with 1 or more of 12
oncogenic HPV types (deﬁned herein),
and who were randomized, vaccinated,
and followed for a period of approxi-
mately 4.75 years (median follow-up
56.7 months; interquartile range
52.466.5). The second consisted of
participants who were randomized and
vaccinated, who at some time during
follow-up received LEEP treatment
for cervical precancer, and who wereAUGUST 2016 Amerifollowed after treatment (median
follow-up 27.3 months; interquartile
range 15.339.8) as part of their
participation in the larger trial. This
latter group should not be considered
formally randomized, because random-
ization occurred at entry into the main
trial and not at the time of LEEP treat-
ment. For both groups of women, we
performed analyses at the infection level,
as described herein. The trial was
reviewed and approved by the US
National Cancer Institute and Costa Rica
INCIENSA Institute (Instituto Costar-
riciense de Investigacion y Ensenanza en
Nutricion y Salud) human subjects re-
view committees. Participants provided
written informed consent.
At enrollment and during the follow-
up period, risk factor questionnaires
were administered and pelvic examina-
tions performed on sexually experienced
women. Specimens were collected at
those visits to allow for ThinPrep
cytology (Hologic, Marlborough, MA)
and HPV DNA testing. Cytology was
interpreted via use of the Bethesda sys-
tem.13 Women with cytologic evidence
of high-grade precancer and those with
evidence of persistent low-grade cervical
lesions were referred to colposcopy for
further evaluation and disease ascer-
tainment. For those referred to colpos-
copy, biopsies were collected when
cervical lesions were evident and treat-
ment by LEEP performedwhen clinically
indicated. Hematoxylin and eosin slides
prepared from formalin-ﬁxed and
parafﬁn-embedded materials were used
to grade the lesions by the study
pathologist in Costa Rica, followed by
independent review by a second pathol-
ogist in the United States. When grades
were discrepant, a third US pathologist
blindly evaluated the slides to adjudicate
and establish the ﬁnal diagnosis for
analytical purposes.
HPV HC2 testing (Digene Corpora-
tion, Silver Spring, MD) with the use of
PreservCyt solution (Cytyc Corporation,
Marlborough, MA) was performed as
per the manufacturer’s instructions14 on
all enrollment (prevaccination) speci-
mens, all specimens collected at the ﬁnal
blinded visit, and to triage equivocal
cytology results (atypical cells ofcan Journal of Obstetrics& Gynecology 212.e2
FIGURE 1
Study consort diagrams
A, Consort e evaluation of prevalent HPV infections. B, Consort e evaluation of recurrence after
LEEP.
HPV, human papillomavirus; HAV, hepatitia A virus; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical
excisional procedure.
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follow-up. Broad-spectrum polymerase
chain reactionbased HPV DNA testing
was performed on cells stored in Pre-
servcyt solution at all study timepoints
using a previously described procedure
based on ampliﬁcation with the SPF10
primers, a DNA enzyme immunoassay
detection of amplimers, and typing us-
ing the LiPA line blot detection system
(LiPA HPV InnoLiPA HPV genotyping
assay SPF10 system, version 1, Labo
Bio-medical Products, Rijswijk, the
Netherlands).15-17 The LiPA detects 25
HPV genotypes, including the 12 onco-
genic HPV types of interest for this
evaluation (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59). To ensure that HPV-16
and HPV-18 infections were not
missed, all specimens that screened
positive for HPV DNA via the SPF10
DNA enzyme immunoassay but that
were negative for HPV-16 or HPV-18 by
LiPA were tested for the presence of
HPV-16 and HPV-18 DNA with the use
of type-speciﬁc primers, as previously
described.17
A total of 7466 women were enrolled
and randomized in our trial. Of these,
the 1901 (954 HPV arm; 947 control
arm) who tested positive for 1 ormore of
12 oncogenic HPV types at randomiza-
tion were considered for the infection-
level analysis that evaluated the fate of
HPV infections present at the time of
vaccination (Figure 1, A). We further
excluded from this analysis 1 woman
who received a discordant vaccine (0
HPV arm; 1 control arm), 150 women
who had evidence of high-grade disease
requiring treatment at enrollment (83
HPV arm; 67 control arm), and 39
women with no follow-up time after
enrollment (19 HPV arm; 20 control
arm).
Women included in this analytical
cohort (N¼1711; 8588 person years of
follow-up) had a median of 7 study visits
after enrollment (7, interquartile range
58 HPV arm; 7, interquartile range
58 control arm) and were followed for
a median of 56.7 months (56.4, inter-
quartile range 52.066.1 HPVarm; 57.0,
interquartile range 52.766.8 control
arm). They had a total of 2434 oncogenic
HPV infections at enrollment (1198
TABLE 1
Enrollment characteristics of women included in the prevalent infection
cohort, by vaccination arm
Variables Control arm, n (%) HPV arm, n (%)
Number of women 859 (50.2%) 852 (49.8%)
Age at entry, years
<20 261 (30.4%) 228 (26.8%)
2021 213 (24.8%) 234 (27.5%)
2223 206 (24.0%) 206 (24.2%)
>23 179 (20.8%) 184 (21.6%)
Lifetime no. partnersa
1 244 (28.6%) 249 (29.3%)
2 231 (27.0%) 237 (27.8%)
3þ 379 (44.4%) 365 (42.9%)
Costa Rica cytology
Normal 612 (71.2%) 583 (68.4%)
Abnormal 247 (28.8%) 269 (31.6%)
Histology
Normal 819 (95.3%) 820 (96.2%)
CIN1þ 40 (4.7%) 32 (3.8%)
HPV infection status
Single 583 (67.9%) 590 (69.2%)
Multiple 276 (32.1%) 262 (30.8%)
HPV analysis group (nonexclusive groups)
HPV-16/18 299 (34.8%) 256 (30.0%)
HPV-31/33/45 207 (24.1%) 197 (23.1%)
HPV-Oncogenic 859 (100%) 852 (100%)
+, or greater; CIN1, cervical intraepithelial neoplasia type 1; HPV, human papillomavirus.
a Six women missing lifetime number of partners information (5 control; 1 HPV) were excluded.
Hildesheim et al. HPV vaccination after infection and/or treatment. Am J Obstet Gynecol 2016.
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with women included in our previous
publication on this topic,6 this analysis
included an additional 106 women
(6.6% increase) and 7136 person years of
follow-up (491% increase). Comparison
of this analytical cohort by study arm
revealed balance with respect to age,
lifetime number of partners, cytology
results, and HPV status (single vs mul-
tiple infections; HPV type) at enrollment
(Table 1).
For the infection-level analysis that
evaluated recurrence after treatment, we
considered 370 women (172 HPV arm;
198 control arm) who were treated withLEEP during the follow-up period
(Figure 1, B). We further excluded 41
women (21 HPV arm; 20 control arm)
who had a LEEP performed but for
whom there was no evidence of high-
grade disease before the procedure and
18 women (9 HPV arm; 9 control arm)
who had no follow-up after treatment.
A total of 311 women were therefore
included in the analysis (142 HPV arm;
169 control arm). A total of 130 of these
women also were included in the
analytical cohort of women infected at
entry that was described in the preceding
paragraph. Women included in this
analytical cohort had amedian of 3 studyAUGUST 2016 Amerivisits after treatment (4, interquartile
range 35 HPV arm; 3, interquartile
range 25 control arm) and were fol-
lowed for a median of 27.3 months after
treatment (31.8, interquartile range
19.639.8 HPV arm; 23.9, interquartile
range 11.5-39.8 control arm). These
women had a total of 156 oncogenic
HPV infections detected after treatment
(71 HPV arm; 85 control arm). Com-
parison of this analytical cohort by study
arm revealed balance with respect to age
at enrollment (Table 2).
Given the high efﬁcacy of the HPV-
16/18 vaccine against new infections
and associated lesions, women in the
HPVarm for this analytical cohort were
relatively more likely to have a LEEP
early in the study to treat a condition
that was prevalent at enrollment and
conversely less likely to have a LEEP
later in the study to treat an incident
condition arising from an infection
initiating after vaccination (23.9% and
39.6% for HPV arm and Control arm
had LEEP performed to treat lesions
caused by incident infections, respec-
tively). As a result, the median number
of months between enrollment and
treatment was 28.2 for those in the HPV
arm (interquartile range 15.244.6
months) and 38.1 for women in the
control arm (interquartile range
22.450.5 months). We also observed a
greater proportion of women in the
HPV arm (compared with the control
arm) who reported 2þ partners and
who had an abnormal cytology at
enrollment, and a lower proportion of
women in the HPVarm (compared with
the control arm) who were HPV DNA
negative at enrollment (Table 2).
We chose to use an infection rather
than a woman as the unit of analysis
because of our interest in the fate of in-
dividual HPV infections. A total of
31.4% of infected women hadmore than
1 HPV type at enrollment. We evaluated
the following HPV categories: HPV-16/
18 (HPV-16 and/or HPV-18—the pri-
mary vaccine types), HPV-31/33/45
(HPV-31 and/or HPV-33 and/or HPV-
45—HPV types for which evidence for
cross-protection has been documented),
and oncogenic types (any of the 12
oncogenic HPV types).can Journal of Obstetrics& Gynecology 212.e4
TABLE 2
Enrollment characteristics of women included in the recurrence cohort,
by vaccination arm
Variables Control arm, n (%) HPV arm, n (%)
Number of women 169 142
Age at entry, years
<20 37 (21.9%) 31 (21.8%)
2021 38 (22.5%) 36 (25.3%)
2223 53 (31.4%) 38 (26.8%)
>23 41 (24.3%) 37 (26.1%)
Lifetime no. partners
Unknown 2 (1.2%) 0 (0.0%)
Virgin 15 (8.9%) 3 (2.1%)
1 48 (28.4%) 33 (23.2%)
2 40 (23.7%) 42 (29.6%)
3þ 64 (37.9%) 64 (45.1%)
Cytology result
Inadequate 1 (0.6%) 2 (1.4%)
Normal 97 (57.4%) 57 (40.1%)
LSIL 31 (18.3%) 36 (25.4%)
HSILþ 40 (23.7%) 47 (33.1%)
HPV DNA (Hierarchical - HPV-16/18, HPV-31/33/45,
Other-onco, Non-onco, Negative)
Negative 34 (20.1%) 13 (9.2%)
HPV 16/18-positive 64 (37.9%) 55 (38.7%)
HPV 31/33/45-positive 19 (11.2%) 24 (16.9%)
Other oncogenic-positive 33 (19.5%) 36 (25.4%)
Nononcogenic-positive 19 (11.2%) 14 (9.9%)
+, or greater; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous
intraepithelial lesion.
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sions occurring among women infected
at entry, we considered the following
outcomes: type-speciﬁc viral clearance
and development of histologically
conﬁrmed cervical lesions (CIN1þ and
CIN2þ). In a subanalysis restricted to
infected women with normal cytology,
we also considered as an outcome the
development of cytologically evident le-
sions (low-grade squamous intra-
epithelial lesion or greater and high-
grade squamous intraepithelial lesion
or greater).
For the evaluation of women treated
by LEEP, we considered the following
outcomes after LEEP: HPV infection,
persistent HPV infection (deﬁned as
detection of type-speciﬁc HPV at 2 or
more consecutive visits after treatment),
squamous intraepithelial lesion (SIL),
and CIN2þ. We also conducted sub-
analyses that considered outcomes
associated with HPV types present and
absent before treatment, separately.
Sensitivity analyses were performed
restricted to women whose LEEP was
performed to treat conditions prevalent
at enrollment, to ensure that ﬁndings
were not driven by the differential pro-
portion of incident outcomes observed
between study arms. As results from
these sensitivity analyses were similar to
those observed for our main analyses,
they are not presented further.
Vaccine efﬁcacy, a measure of the
percent reduction (or increase) in
outcome rates observed when the HPV
arm is compared against the control arm,
was computed, along with the corre-
sponding 95% conﬁdence interval (95%
CI) around vaccine efﬁcacy estimates.
The generalized estimating equations
method was used to account for possible
lack of independence between clearance
in analysis of more than one infection in
the same woman. The estimates of rates
of infection that clear from the general-
ized estimating equations analysis
can, therefore, be slightly different from
the crude percentages. We present cu-
mulative vaccine efﬁcacy against persis-
tence for several HPV categories. In
addition, to cumulative analyses, curves
depicting the fate of prevalent infections
over time were also developed.212.e5 American Journal of Obstetrics& GynecolResults
Impact of HPV-16/18 vaccination on
infections prevalent at vaccination
We ﬁrst evaluated whether rates of viral
clearance and/or progression to cervical
preneoplastic lesions differed by vacci-
nation status. Results are summarized in
Table 3. We found no evidence that
HPV-16/18 vaccination altered the fate
of an HPV infection present at the time
of vaccination. When we evaluated
HPV-16/18 infections, for example,
vaccine efﬁcacy was 5.4% (95%
CI19, 10) for clearance,15.5% (95%
CI 86, 28) for progression to CIN1þ,
and 0.3% (95% CI 69, 41) for pro-
gression to CIN2þ in the cohort ofogy AUGUST 2016women with HPV infection but without
precancer. A similar lack of vaccination
effect was observed when we evaluated
infections with HPV-31/33/45 (HPV
types for which evidence for partial
cross-protection against incident in-
fections and lesions was previously
demonstrated) or infections with any
oncogenic HPV. These results were
consistent when the more restricted
cohort of women without cytologic ab-
normalities at vaccination was evaluated,
and among this more restricted cohort
when progression to low-grade or high-
grade SIL were evaluated. Time-
dependent curves depicting the fate of
prevalent infections are provided as
TABLE 3
Impact of HPV-16/18 vaccination on infections prevalent at vaccination
HPV Types Cohort Outcome Arm
No.
infections
No.
events
No. person-
years
Rate per
1000
% vaccine
efficacy 95% CI
HPV-16/18 Infected women
without precancer
Clearance HPV 268 243 492 489 5.4% [19, 10]
Ctrl 313 298 569 517
CIN1þ HPV 244 32 1201 28.0 15.5% [86, 28]
Ctrl 295 35 1427 24.2
CIN2þ HPV 258 25 1301 20.2 0.3% [69, 41]
Ctrl 308 31 1504 20.3
Infected women without
cytologic abnormalities
Clearance HPV 173 160 326 481 3.3% [19, 16]
Ctrl 216 208 403 497
LSILþ HPV 171 62 642 77.2 3.5% [85, 42]
Ctrl 216 71 861 74.6
HSILþa HPV 161 23 744 30.9 48.6% [172, 19]
Ctrl 200 20 961 20.8
CIN1þ HPV 171 23 835 28.5 5.5% [60, 44]
Ctrl 214 32 1035 30.2
CIN2þ HPV 171 17 849 20.7 22.6% [40, 57]
Ctrl 215 29 1050 26.8
HPV-31/33/45 Infected women
without precancer
Clearance HPV 214 206 323 617 4.0% [13, 24]
Ctrl 222 211 348 594
CIN1þ HPV 201 17 938 18.3 14.0% [62, 54]
Ctrl 210 22 1020 21.3
CIN2þ HPV 208 14 986 14.4 17.4% [65, 59]
Ctrl 218 19 1070 17.4
Infected women without
cytological abnormalities
Clearance HPV 144 138 219 617 9.3% [12, 35]
Ctrl 159 151 261 564
LSILþ HPV 144 32 578 52.4 4.2% [79, 39]
Ctrl 158 41 662 50.3
HSILþ HPV 144 13 653 20.1 4.2% [101, 54]
Ctrl 158 17 749 21
CIN1þ HPV 144 14 656 21.5 17.6% [63, 58]
Ctrl 157 20 753 26.1
CIN2þ HPV 144 12 663 18.2 15.7% [76, 60]
Ctrl 157 17 763 21.6
Oncogenic HPV Infected women
without precancer
Clearance HPV 1198 1149 1761 599 4.8% [3.7, 14]
Ctrl 1236 1184 1881 571
CIN1þ HPV 1110 83 5487 14.0 0.9% [42, 28]
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TABLE 3
Impact of HPV-16/18 vaccination on infections prevalent at vaccination (continued)
HPV Types Cohort Outcome Arm
No.
infections
No.
events
No. person-
years
Rate per
1000
% vaccine
efficacy 95% CI
Ctrl 1149 89 5646 13.9
CIN2þ HPV 1160 62 5817 9.6 3.1% [45, 35]
Ctrl 1208 68 6004 9.9
Infected women without
cytologic abnormalities
Clearance HPV 788 758 1195 575 1.0% [8.8, 12]
Ctrl 854 822 1311 569
LSILþ HPV 779 191 3242 45.2 10.7% [45, 16]
Ctrl 847 197 3615 40.8
HSILþ HPV 779 64 3750 14.3 19.2% [84, 23]
Ctrl 847 62 4128 12
CIN1þ HPV 779 62 3814 15.5 6.7% [35, 35]
Ctrl 842 76 4130 16.6
CIN2þ HPV 779 46 3862 10.8 15.0% [31, 45]
Ctrl 845 59 4188 12.8
+, or greater; CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; HPV, human papillomavirus; HSIL, high-grade squamous
intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.
a Excludes 5 individuals from the HPV arm and 8 individuals from the control arm with both HPV16 and HPV18 infections to allow for model conversion.
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again, do not suggest any measurable
effect of vaccination on either clearance
or progression of prevalent infections.
Impact of HPV-16/18 vaccination on
rate of HPV infections and cervical
lesions after LEEP
Next, we evaluated whether rates of
cervical infections and lesions after
excisional treatment by LEEP differed by
vaccination status. Overall, 34.1% of the
311 women included in this analysis had
1þ oncogenic HPV infections and 1.6%
had CIN2þ detected after treatment,
respectively. Among this subset, 69.8%
of infection and 20.0% of CIN2þ lesions
were the result of new HPV infections
absent before treatment. This ﬁnding
highlights the effectiveness of LEEP as a
treatment for cervical precancers and the
fact that disease recurrence is a rare event
after treatment. We observed no evi-
dence for a signiﬁcant effect of vaccina-
tion when we evaluated HPV-16/18
infections and/or HPV-16/18 associated
cytologic/histologic lesions after LEEP
(Table 4). Similar patterns were observed212.e7 American Journal of Obstetrics& Gynecolwhen we evaluated HPV-31/33/45,
oncogenic HPV, and outcomes irre-
spective of HPV type, with the exception
of a signiﬁcant vaccine efﬁcacy observed
for any HPV-31/33/45 infection
outcome (vaccine efﬁcacy 56.9%; 95%
CI 8.2, 80) (Table 4).
Because the HPV-16/18 vaccine has
been proven to protect against new HPV
infections and their associated lesions,
we next evaluated whether there was
evidence for vaccine efﬁcacy against
infection and cytologic/histologic lesions
after treatment for infections that
were newly detected after treatment
(ie, excluding infections and lesions
associated with infections that were
evident before treatment) (Table 4;
Supplemental Tables 1 and 2). Although
numbers and statistical power were
limiting, vaccine efﬁcacy estimates were
consistently positive in this restricted
analysis. In some instances, the vaccine
efﬁcacy observed reached statistical sig-
niﬁcance. When HPV infection was
examined as the outcome, for example,
we observed a nonsigniﬁcant but posi-
tive vaccine efﬁcacy estimate of 57.9%ogy AUGUST 2016(95% CI 43, 88) for HPV-16/18, a
signiﬁcant positive vaccine efﬁcacy
estimate of 72.9% (95% CI 29, 90) for
HPV-31/33/45, and a signiﬁcant positive
vaccine efﬁcacy estimate of 36.7% (95%
CI 1.5, 59) for oncogenic HPVs.
Discussion
The ability of HPV virus-like particle
vaccines to prevent new infections and
their associated lesions has been clearly
demonstrated.1-3 This high prophylactic
efﬁcacy is likely explained by the induc-
tion of neutralizing antibodies that pro-
tect against infection by binding to
virions and preventing them from
infecting human cells.4 Whether HPV
vaccination beneﬁts individuals already
infected with HPV is less well under-
stood. Initial reports suggested that
vaccination of women already infected
with HPV did not affect the fate of
detectable infections,6-8 but more recent
reports have raised the possibility of
beneﬁt in another group of women with
a history of infection—women who
receive treatment for HPV-associated
disease.9-11 To what extent vaccination
TABLE 4
Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP
HPV types Outcome Arm
Overall analysis
Analysis restricted to newly detected
HPV infections after treatment
Total no. events
(# Prevalent/
# Incident)
No.
person-
years
Rate per
1000
% vaccine
efficacy 95% CI
Rate per
1000
% vaccine
efficacy
(incident)
95% CI
(incident)
HPV-16/18 HPV infection HPV 12 (8/4) 678 18.2 25.2% [58, 65] 7.6 57.9% [43, 88]
Ctrl 16 (8/8) 664 24.4 18.0
Persistent
HPV
HPV 4 (4/0) 689 5.9 34.7% [131, 82] 0.0 100.0% N/A
Ctrl 6 (4/2) 665 9.1 4.5
LSILþ HPV 4 (4/0) 302 13.2 8.0% [339, 73] 0.0 100.0% N/A
Ctrl 4 (2/2) 326 12.3 6.1
HSILþ HPV 3 (3/0) 348 8.6 58.0% [857, 74] 0.0 100.0% N/A
Ctrl 2 (1/1) 367 5.4 2.7
CIN2þ HPV 3 (3/0) 362 8.3 211.0% [2901, 68] 0.0 N/A N/A
Ctrl 1 (1/0) 375 2.7 0.0
HPV-31/
33/45
HPV infection HPV 9 (4/5) 1038 9.1 56.9% [8.2, 80] 5.7 72.9% [29, 90]
Ctrl 20 (3/17) 989 21.1 21.0
Persistent HPV HPV 2 (2/0) 1049 2.0 76.0% [11, 95] 0.0 100.0% N/A
Ctrl 8 (1/7) 1000 8.2 8.6
LSILþ HPV 5 (3/2) 302 16.5 8.0% [275, 69] 6.6 46.0% [194, 90]
Ctrl 5 (1/4) 326 15.3 12.3
HSILþ HPV 3 (3/0) 348 8.6 0.0 N/A N/A
Ctrl 0 (0/0) 367 0.0 0.0
CIN2þ HPV 0 (0/0) 362 0.0 0.0 N/A N/A
Ctrl 0 (0/0) 375 0.0 0.0
Oncogenic
HPV
HPV infection HPV 71 (25/46) 4097 14.1 24.3% [-7.7, 47] 11.2 36.7% [1.5, 59]
Ctrl 85 (20/65) 3969 18.7 17.7
Persistent HPV HPV 22 (14/8) 4156 4.7 31.7% [-19, 61] 2.2 65.5% [23, 84]
Ctrl 30 (9/21) 4001 6.9 6.5
LSILþ HPV 19 (10/9) 302 62.9 57.9% [225, 23] 29.8 2.8% [140, 61]
Ctrl 13 (3/10) 326 39.8 30.6
HSILþ HPV 7 (6/1) 348 20.1 145.8% [859, 37] 2.9 47.3% [480, 95]
Ctrl 3 (1/2) 367 8.2 5.4
CIN2þ HPV 3 (3/0) 362 8.3 55.5% [834, 74] 0.0 100.0% N/A
Ctrl 2 (1/1) 375 5.3 2.7
Irrespective
of HPV
LSILþ HPV 33 302 109.2 15.0% [89, 30]
Ctrl 31 326 95.0
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TABLE 4
Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP (continued)
HPV types Outcome Arm
Overall analysis
Analysis restricted to newly detected
HPV infections after treatment
Total no. events
(# Prevalent/
# Incident)
No.
person-
years
Rate per
1000
% vaccine
efficacy 95% CI
Rate per
1000
% vaccine
efficacy
(incident)
95% CI
(incident)
HSILþ HPV 10 348 28.7 163.3% [742, 18]
Ctrl 4 367 10.9
CIN2þ HPV 3 362 8.3 55.5% [834, 74]
Ctrl 2 375 5.3
+, or greater; CI, confidence interval; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop elec-
trosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available.
Hildesheim et al. HPV vaccination after infection and/or treatment. Am J Obstet Gynecol 2016.
Original Research GYNECOLOGY ajog.orghelps prevent infection and disease after
treatment and whether any beneﬁt of
vaccination in this group of women is
explained by prevention of new in-
fections after treatment vs protection
against recurrence of already existing
infections has not been determined.
To clarify these issues, we conducted a
comprehensive evaluation within a large
randomized clinical trial of young adult
women in Costa Rica in which we eval-
uated both the impact of vaccination on
prevalent infection and the effect of
vaccination on post-treatment in-
fections/disease. Our results reinforce
the notion that HPV vaccination is
prophylactic and does not provide sec-
ondary beneﬁt. First, we conﬁrmed that
there are no differences in rates of viral
clearance or progression among women
infected at the time of vaccination. Sec-
ond, we report no evidence for a reduc-
tion in the rates of post-LEEP infections
and/or disease after vaccination. Addi-
tional analyses did suggest one subgroup
of women that might beneﬁt from
vaccination—women exposed to new
HPV infections after treatment. For this
subgroup, our evaluation observed sig-
niﬁcant vaccine efﬁcacy against the
development of new infections associ-
ated with HPV-31/33/45 and oncogenic
infections, and nonsigniﬁcant but sug-
gestive evidence for vaccine efﬁcacy
against new infections associated with
HPV-16/18. We were unable to
convincingly demonstrate similar pro-
tection against cervical lesions (SIL and212.e9 American Journal of Obstetrics& GynecolCIN2þ) associated with these new HPV
infections, given the small number of
such events in our study; nonetheless,
vaccine efﬁcacy estimates were sugges-
tive of protection against lesions caused
by new HPV infections after treatment, a
topic that deserves consideration in
future studies. It warrants mention that,
consistent with the high curative rate of
LEEP, our evaluation highlights that
rates of cervical disease after treatment
are low and that only a small fraction of
this disease is caused by new infections
that were not already evident at the time
of treatment. This ﬁnding suggests that,
in contrast to the proven beneﬁt of
vaccinating young adolescents to prevent
initial HPV infection and subsequent
disease, any potential impact of vacci-
nation targeting women who either have
a detectable HPV infection and/or
receive treatment for HPV-associated
disease is likely small at best.
Strengths of our study include the
random assignment of women into study
arms, its community-based design, the
large size of our cohort (7466 women
total), and the blinded, active follow-upof
participants over 4 years after vaccination.
Limitations of our study include the
modest number of women who required
treatment for cervical precancer during
the study period and the imbalances by
study arm created during follow-up due
to the high prophylactic efﬁcacy of the
vaccine and the resultant smaller pro-
portion of women who required treat-
ment for incident disease on the HPVogy AUGUST 2016compared to control arm of the study.
This latter limitation is mitigated by the
fact that sensitivity analyses restricted to
women treated for precancer lesions
identiﬁed at enrollment (ie, at randomi-
zation) yielded similar results.
In summary, our analysis supports a
lack of secondary/therapeutic beneﬁt
fromHPV vaccination and indicates that
beneﬁt of vaccinating women who
receive treatment for HPV-associated
disease suggested by previous reports is
likely limited to the small number of
women with disease caused by new HPV
infections after treatment. n
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SUPPLEMENTAL FIGURE 1
Fate of HPV infections present at the time of vaccination: cohort of women
without high-grade disease
HPV, human papillomavirus.
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SUPPLEMENTAL FIGURE 2
Fate of HPV infections present at the time of vaccination-cohort of women
without low grade or high grade disease
Hildesheim et al. HPV vaccination after infection and/or treatment. Am J Obstet Gynecol 2016.
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SUPPLEMENTAL TABLE 1
Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP (prevalent infections)
HPV types Arm No. trials No. events (infections) No. person-years Rate per 1000 %VE 95% CI
HPV-16/18 HPV 66 8 153 52.5
Ctrl 115 8 223 36.0 e46.0% [e302, 47]
HPV-31/33/45 HPV 52 4 126 31.8
Ctrl 81 3 142 21.2 e50.1% [e595, 68]
HPV-Onco HPV 263 25 592 40.0
Ctrl 422 20 787 24.2 e65.4% [e204, 10]
No. events
(persistent infections)
HPV-16/18 HPV 66 4 156 25.7
Ctrl 114 4 225 17.9 e44.2% [e498, 65]
HPV-31/33/45 HPV 52 2 128 15.6
Ctrl 80 1 142 7.0 e121.6% [e2409, 80]
HPV-Onco HPV 263 14 612 21.3
Ctrl 419 9 790 10.6 e100.5% [e389, 18]
No. events (LSIL+)
HPV-16/18 HPV 142 4 302 13.2
Ctrl 169 2 326 6.1 e116.0% [e1092, 61]
HPV-31/33/45 HPV 142 3 302 9.9
Ctrl 169 1 326 3.1 e224.0% [e3048, 67]
HPV-Onco HPV 142 10 302 33.1
Ctrl 169 3 326 9.2 e260.0% [e1230, 2.5]
No. events (HSIL+)
HPV-16/18 HPV 142 3 348 8.6
Ctrl 169 1 367 2.7 e216.0% [e2961, 67]
HPV-31/33/45 HPV 142 3 348 8.6
Ctrl 169 0 367 0.0 N/A N/A
HPV-Onco HPV 142 6 348 17.2
Ctrl 169 1 367 2.7 e532.0% [e5183, 24]
No. events (CIN2+)
HPV-16/18 HPV 142 3 362 8.3
Ctrl 169 1 375 2.7 e211.1% [e2901, 68]
HPV-31/33/45 HPV 142 0 362 0.0
Ctrl 169 0 375 0.0 N/A N/A
HPV-Onco HPV 142 3 362 8.3
Ctrl 169 1 375 2.7 e211.1% [e2901, 68]
CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intra-
epithelial lesion; LEEP, loop electrosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; VE, vaccine efficiency.
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SUPPLEMENTAL TABLE 2
Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP (new infections)
HPV types Arm No. trials No. events (infections) No. person-years Rate per 1000 %VE 95% CI
HPV-16/18 HPV 206 4 526 7.6
Ctrl 209 8 441 18.0 57.9% [e43, 88]
HPV-31/33/45 HPV 356 5 912 5.7
Ctrl 405 17 847 21.0 72.9% [29, 90]
HPV-Onco HPV 1369 46 3504 11.2
Ctrl 1522 65 3182 17.7 36.7% [1.5, 59]
No. events
(persistent infections)
HPV-16/18 HPV 206 0 533 0.0
Ctrl 208 2 441 4.5 100.0% N/A
HPV-31/33/45 HPV 356 0 920 0.0
Ctrl 404 7 858 8.6 100.0% N/A
HPV-Onco HPV 1369 8 3544 2.2
Ctrl 1517 21 3211 6.5 65.5% [23, 84]
No. events (LSIL+)
HPV-16/18 HPV 142 0 302 0.0
Ctrl 169 2 326 6.1 100.0% N/A
HPV-31/33/45 HPV 142 2 302 6.6
Ctrl 169 4 326 12.3 46.0% [e194, 90]
HPV-Onco HPV 142 9 302 29.8
Ctrl 169 10 326 30.6 2.8% [e140, 61]
No. events (HSIL+)
HPV-16/18 HPV 142 0 348 0.0
Ctrl 169 1 367 2.7 100.0% N/A
HPV-31/33/45 HPV 142 0 348 0.0
Ctrl 169 0 367 0.0 N/A N/A
HPV-Onco HPV 142 1 348 2.9
Ctrl 169 2 367 5.4 47.3% [e480, 95]
No. events (CIN2+)
HPV-16/18 HPV 142 0 362 0.0
Ctrl 169 0 375 0.0 N/A N/A
HPV-31/33/45 HPV 142 0 362 0.0
Ctrl 169 0 375 0.0 N/A N/A
HPV-Onco HPV 142 0 362 0.0
Ctrl 169 1 375 2.7 100.0% N/A
CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intra-
epithelial lesion; LEEP, loop electrosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; VE, vaccine efficiency.
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